Cost greatest barrier to Avastin use, research reveals

The cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are the most common factors preventing oncologists’ use of the...

NICE ‘unable’ to recommend Alimta

NICE has revealed that, due to data uncertainties, it is unable to recommend Alimta (pemetrexed) for the maintenance treatment non-small-cell lung cancer. The draft...

Telehealth gets to the heart of the problem

Bristol-based The Orchard Medical Centre has received a healthcare industry award for its use of telehealth solutions from Tunstall Healthcare to improve care for...

Winners of Medtech Business prize draw

Sales Managers from three medtech companies have won the Medtech Business prize draw from all those who subscribed to the journal at the Association...

ConvaTec recruits Territory Manager

Stoma care specialist ConvaTec has further expanded its UK sales force with the appointment of Sian Ford as Territory Manager for the West Midlands....

Sir Liam Donaldson to retire

England’s Chief Medical Officer, Sir Liam Donaldson, has decided to step down in May 2010 after 12 years of service. Appointed in 1998, Sir...

Patent box holds good news for medtech

The announcement in the Pre-Budget Report (9 December) of a 'patent box' mechanism to reduce corporation tax on innovative activity has been praised by...

Kneehab rebuilds leg muscles

An electrotherapy system now available in the UK can reverse thigh muscle wastage in people recovering from knee injuries. Kneehab from Mobilis Rolyan...

NICE launches ‘must-read’ commissioning guide

The National Institute for Health and Clinical Excellence has launched a new guide illustrating the support available from NICE and benefits of using NICE...

Evidence supports Tyverb-Herceptin combination therapy

Women with an aggressive form of breast cancer could live longer if treated with a combination of Tyverb (lapatinib) plus Herceptin (trastuzumab), recent trial...

Latest articles

Image of a contract being signed to show Novartis Cosentyx® receives EU approval for first-line systemic treatment in paediatric psoriasis

Novartis Cosentyx® receives EU approval for first-line systemic treatment in paediatric psoriasis

Novartis has announced that Cosentyx® has received EU approval for first-line systemic treatment in paediatric psoriasis. The European Commission (EC) has granted the approval for...
Iage of a healthcare professional in PPE to show Roll out of rapid coronavirus tests ahead of winter

Roll out of rapid coronavirus tests ahead of winter

Millions of rapid coronavirus tests will be rolled out to hospitals, care homes and labs across the UK to increase testing capacity ahead of...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Woman holding swab: COVID-19 pandemic

COVID-19: Pharma on the frontline

Pharma stepped up to support the NHS, the country and the World during the COVID-19 pandemic. Pf brings you some examples of pharma on...
Medical tests: rapid change of clinical research

Rapid change COVID-19 & UK clinical research

Dr Matthew Hallsworth, Head of External Relations at the National Institute for Health Research, looks how COVID-19 has brought about rapid change of clinical...
Meeting on ipad: COVID-19 pharma workforce

COVID-19: changing the pharma workforce

There’s no denying the COVID-19 has changed the world, but will it have a lasting effect on the pharma workforce? Graham Hawthorn Managing Director, CHASE It is...
Woman itching skin: Psoriasis skin condition

Getting under the skin of psoriasis

Psoriasis affects around 2% of the population. Although seen as a skin condition, it is an immune condition which can have a physical and...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription